LY3541860

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for LY3541860, covering 2026-04-07 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis [Phase 2]